🟠 Moderate Evidence
Meta-analyses regularly headline coffee as either cardioprotective or harmful, yet these sweeping conclusions mask a crucial truth: whether coffee raises your cardiovascular risk depends almost entirely on a single genetic variant. A polymorphism in the CYP1A2 enzyme—responsible for metabolising roughly 95% of ingested caffeine—determines whether you clear coffee quickly or accumulate it in your bloodstream, fundamentally altering its cardiac effects.
Key takeaways
- CYP1A2 rs762551 polymorphism divides the population into fast, intermediate, and slow caffeine metabolisers; about 55% carry at least one slow allele
- Slow metabolisers drinking ≥4 cups daily show 64% increased odds of nonfatal myocardial infarction; fast metabolisers show no increased risk at the same intake
- Age amplifies the genetic effect: slow metabolisers under 59 drinking ≥4 cups face more than double the MI risk
The CYP1A2 gene controls coffee metabolism
The CYP1A2 enzyme metabolises approximately 95% of the caffeine you consume. A single nucleotide polymorphism—rs762551 (also written −163C>A)—changes how readily the enzyme is induced. Individuals homozygous for the A allele (AA genotype) produce a highly inducible form, clearing caffeine in roughly 3 hours. Those carrying one or two C alleles (AC or CC genotypes) have reduced enzyme inducibility, with half-lives extending to 6–10 hours.
In populations of European descent, the distribution is striking: approximately 45% are fast metabolisers (AA), 44% are intermediate or slow (AC), and 11% are slow metabolisers (CC). This means about 55% of people carry at least one slow allele, making them physiologically susceptible to caffeine accumulation.
CYP1A2 Genotype Distribution and Caffeine Clearance
Frequency and plasma half-life by rs762551 polymorphism in European populations
Source: CYP1A2 rs762551 polymorphism frequency data | Georgian Medical Journal News
Costa Rican study shows stark gene-by-coffee interaction
The clinical significance of this genetic difference emerged clearly in research by Cornelis and colleagues, published in JAMA (2006). Their case-control study enrolled 2,014 individuals with first nonfatal myocardial infarction and 2,014 matched controls in Costa Rica. The results revealed a striking gene-environment interaction:
Among slow caffeine metabolisers, consuming 4 or more cups of coffee daily was associated with an odds ratio of 1.64 for nonfatal myocardial infarction (95% CI, 1.14–2.34). Among fast metabolisers consuming the same amount, the odds ratio was 0.99 (0.66–1.48)—essentially no increased risk. The interaction was statistically significant (p = 0.04).
— Cornelis et al., JAMA (2006)
The disparity widened dramatically in younger participants. Among slow metabolisers under age 59 drinking ≥4 cups daily, the odds ratio reached 2.33 (95% CI, 1.39–3.89)—more than double the baseline risk. Fast metabolisers in the same age group showed no increased risk. This age-stratified finding suggests that cumulative caffeine exposure may trigger arrhythmias or ischaemic events more readily in younger individuals with genetic predisposition.
Hypertension findings corroborate the genetic mechanism
Additional evidence from Palatini and colleagues, published in the Journal of Hypertension (2009), examined blood pressure responses to coffee in 553 young Italian adults. Their work reinforces that slow metabolisers experience acute and sustained blood pressure elevations after caffeine intake, whereas fast metabolisers show minimal haemodynamic effects. These findings align with the JAMA results, suggesting a unified physiological mechanism: slow metabolisers accumulate caffeine to levels that trigger sympathomimetic and arrhythmogenic effects, elevating both blood pressure and ischaemic risk.
The consistency of this gene-by-coffee interaction across different populations and disease endpoints—myocardial infarction in Costa Ricans, hypertension in Italians—indicates that the CYP1A2 polymorphism is not a quirk of one population but a robust predictor of individual susceptibility. Visit our coverage of recent cardiovascular studies for more evidence-based perspectives on modifiable risk factors, and see detailed health explainers for personalised guidance on caffeine intake.
What this means
Frequently asked questions
Can I get tested for my CYP1A2 status?
Yes. Genetic testing for rs762551 is available through direct-to-consumer and clinical genomics laboratories. However, clinical uptake remains limited in primary care. If you have a personal or family history of early-onset myocardial infarction, hypertension, or arrhythmia, ask your clinician about pharmacogenomic testing as part of your risk assessment.
Does this finding apply to other caffeinated beverages?
Yes. The CYP1A2 polymorphism affects the metabolism of all dietary caffeine sources—tea, energy drinks, and cola—equally. Total caffeine intake, not the beverage type, determines plasma accumulation and cardiac effects in slow metabolisers.
Why do meta-analyses keep showing conflicting results?
Most meta-analyses do not stratify by CYP1A2 genotype, pooling fast and slow metabolisers together. This dilutes protective effects in fast metabolisers and obscures harmful effects in slow metabolisers, generating ambiguous headlines. Future analyses should include genetic stratification to resolve apparent contradictions.
The next generation of dietary cardiovascular research must move beyond crude population averages. As genomic data become cheaper and more accessible, precision prevention—tailoring caffeine advice to individual CYP1A2 status—offers a concrete example of how genetic knowledge can refine clinical practice and improve outcomes in common, modifiable risk factors. Read more on clinical updates to stay informed on how personalised medicine is reshaping cardiovascular prevention.
Source: Coffee metabolism and cardiovascular risk: the CYP1A2 gene-environment interaction
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
